Osmoregulation in polycystic kidney disease: relationship with cystogenesis and hypertension

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Polycystic kidney disease (PKD) is a group of monogenetic conditions characterised by the progressive accumulation of multiple renal cysts and hypertension. One of the earliest features of PKD is a reduction in urinary concentrating capacity that impairs extracellular fluid conservation. Urinary concentrating impairment predisposes PKD patients to periods of hypohydration when fluid loss is not adequately compensated by fluid intake. The hypohydrated state provides a blood hyperosmotic stimulus for vasopressin release to minimise further water loss. However, over-activation of renal V2 receptors contributes to cyst expansion. Although suppressing vasopressin release with high water intake has been shown to impair disease progression in rodent models, whether this approach is efficacious in patients remains uncertain. The neural osmoregulatory pathway that controls vasopressin secretion also exerts a stimulatory action on vasomotor sympathetic activity and blood pressure during dehydration. Recurrent dehydration leads to a worsening of hypertension in rodents and cross-sectional data suggests that reduced urinary concentrating ability may contribute to hypertension development in the clinical PKD population. Experimental studies are required to evaluate this hypothesis and to determine the underlying mechanism.

Fingerprint

Osmoregulation
Polycystic Kidney Diseases
Vasopressins
Hypertension
Dehydration
Cysts
Rodentia
Neural Pathways
Vasopressin Receptors
Renal Hypertension
Extracellular Fluid
Drinking
Disease Progression
Blood Pressure
Kidney
Water
Population

Bibliographical note

Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • Blood pressure
  • Hypertension
  • Osmolality
  • Polycystic kidney disease
  • Sympathetic nervous system
  • Urinary concentrating ability
  • Vasopressin

Cite this

@article{4b2cd24b61e34085a9d3bdfdbd8ee8a0,
title = "Osmoregulation in polycystic kidney disease: relationship with cystogenesis and hypertension",
abstract = "Polycystic kidney disease (PKD) is a group of monogenetic conditions characterised by the progressive accumulation of multiple renal cysts and hypertension. One of the earliest features of PKD is a reduction in urinary concentrating capacity that impairs extracellular fluid conservation. Urinary concentrating impairment predisposes PKD patients to periods of hypohydration when fluid loss is not adequately compensated by fluid intake. The hypohydrated state provides a blood hyperosmotic stimulus for vasopressin release to minimise further water loss. However, over-activation of renal V2 receptors contributes to cyst expansion. Although suppressing vasopressin release with high water intake has been shown to impair disease progression in rodent models, whether this approach is efficacious in patients remains uncertain. The neural osmoregulatory pathway that controls vasopressin secretion also exerts a stimulatory action on vasomotor sympathetic activity and blood pressure during dehydration. Recurrent dehydration leads to a worsening of hypertension in rodents and cross-sectional data suggests that reduced urinary concentrating ability may contribute to hypertension development in the clinical PKD population. Experimental studies are required to evaluate this hypothesis and to determine the underlying mechanism.",
keywords = "Blood pressure, Hypertension, Osmolality, Polycystic kidney disease, Sympathetic nervous system, Urinary concentrating ability, Vasopressin",
author = "Underwood, {Conor F.} and Phillips, {Jacqueline K.} and Hildreth, {Cara M.}",
note = "Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2018",
month = "6",
day = "1",
doi = "10.1159/000488125",
language = "English",
volume = "72",
pages = "33--38",
journal = "Annals of Nutrition and Metabolism",
issn = "0250-6807",
publisher = "S. Karger AG",
number = "suppl 2",

}

Osmoregulation in polycystic kidney disease : relationship with cystogenesis and hypertension. / Underwood, Conor F.; Phillips, Jacqueline K.; Hildreth, Cara M.

In: Annals of Nutrition and Metabolism, Vol. 72, No. suppl 2, 01.06.2018, p. 33-38.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Osmoregulation in polycystic kidney disease

T2 - Annals of Nutrition and Metabolism

AU - Underwood, Conor F.

AU - Phillips, Jacqueline K.

AU - Hildreth, Cara M.

N1 - Copyright the Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Polycystic kidney disease (PKD) is a group of monogenetic conditions characterised by the progressive accumulation of multiple renal cysts and hypertension. One of the earliest features of PKD is a reduction in urinary concentrating capacity that impairs extracellular fluid conservation. Urinary concentrating impairment predisposes PKD patients to periods of hypohydration when fluid loss is not adequately compensated by fluid intake. The hypohydrated state provides a blood hyperosmotic stimulus for vasopressin release to minimise further water loss. However, over-activation of renal V2 receptors contributes to cyst expansion. Although suppressing vasopressin release with high water intake has been shown to impair disease progression in rodent models, whether this approach is efficacious in patients remains uncertain. The neural osmoregulatory pathway that controls vasopressin secretion also exerts a stimulatory action on vasomotor sympathetic activity and blood pressure during dehydration. Recurrent dehydration leads to a worsening of hypertension in rodents and cross-sectional data suggests that reduced urinary concentrating ability may contribute to hypertension development in the clinical PKD population. Experimental studies are required to evaluate this hypothesis and to determine the underlying mechanism.

AB - Polycystic kidney disease (PKD) is a group of monogenetic conditions characterised by the progressive accumulation of multiple renal cysts and hypertension. One of the earliest features of PKD is a reduction in urinary concentrating capacity that impairs extracellular fluid conservation. Urinary concentrating impairment predisposes PKD patients to periods of hypohydration when fluid loss is not adequately compensated by fluid intake. The hypohydrated state provides a blood hyperosmotic stimulus for vasopressin release to minimise further water loss. However, over-activation of renal V2 receptors contributes to cyst expansion. Although suppressing vasopressin release with high water intake has been shown to impair disease progression in rodent models, whether this approach is efficacious in patients remains uncertain. The neural osmoregulatory pathway that controls vasopressin secretion also exerts a stimulatory action on vasomotor sympathetic activity and blood pressure during dehydration. Recurrent dehydration leads to a worsening of hypertension in rodents and cross-sectional data suggests that reduced urinary concentrating ability may contribute to hypertension development in the clinical PKD population. Experimental studies are required to evaluate this hypothesis and to determine the underlying mechanism.

KW - Blood pressure

KW - Hypertension

KW - Osmolality

KW - Polycystic kidney disease

KW - Sympathetic nervous system

KW - Urinary concentrating ability

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=85048975187&partnerID=8YFLogxK

U2 - 10.1159/000488125

DO - 10.1159/000488125

M3 - Article

VL - 72

SP - 33

EP - 38

JO - Annals of Nutrition and Metabolism

JF - Annals of Nutrition and Metabolism

SN - 0250-6807

IS - suppl 2

ER -